The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Homeobox B9: A potential surrogate marker for bevacizumab in combination with chemotherapy in colorectal cancer.
Yoshinori Hoshino
No relevant relationships to disclose
Tetsu Hayashida
No relevant relationships to disclose
Akira Hirata
No relevant relationships to disclose
Koji Okabayashi
No relevant relationships to disclose
Hiroki Ochiai
No relevant relationships to disclose
Takashi Endo
No relevant relationships to disclose
Yoshiyuki Ishii
No relevant relationships to disclose
Hiromitsu Jinno
No relevant relationships to disclose
Hirotoshi Hasegawa
No relevant relationships to disclose
Yuko Kitagawa
No relevant relationships to disclose